Report : North America Starch Softgel Capsules Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Application (Pharmaceutical, Health Supplements, Others); Distribution Channel (Supermarket and Hypermarket, Pharmacy and Drugstore, Online Provider)
According to the latest study on “North America Starch Softgel Capsules Market Forecast to 2027 – COVID-19 Impact and Analysis – by Application, , and Distribution Channel,” the market was valued at US$ 139.13 million in 2019 and is projected to reach US$ 202.54 million by 2027; it is expected to grow at a CAGR of 4.9% during 2020–2027. The report highlights trends prevailing in the North America starch softgel capsules market and the factors driving market along with those that act as hindrances.
Based on application, the North America starch softgel capsules market is segmented into pharmaceutical, health supplements, and others. In 2019, the health supplement segment held a larger share of the market. Also, it is expected to grow at a faster rate during the forecast period.
The growth of the North America starch softgel capsules market is attributed to the increasing availability of vegetarian softgel capsules, and rising preference of pharmaceutical and nutraceutical companies toward softgel capsules. However, difficulties in optimizing cellulose/starch for API delivery limits the growth of market in this region.
Catalent Inc, Robinson Pharma, Inc., ProCaps, CAPTEK Softgel International Inc., and Sirio Pharma Co., Ltd. are among the leading companies operating in the North America starch softgel capsules market.
The report segments North America starch softgel capsules Market as follows:
By Distribution Channel